LinkedIn post on Regeneron’s Praluent pricing and market rollout
LinkedIn post on Regeneron’s Praluent pricing and market rollout The passage discusses drug pricing, market expectations, and physician usage surveys for Praluent. It contains no concrete allegations, financial flows, or links to high‑profile political or intelligence actors. The information is largely public and offers no actionable investigative leads. Key insights: Regeneron CEO Leonard Schleifer comments on pricing and access.; Praluent price is 46% higher than analyst forecasts.; Physician survey suggests broader off‑label use than label.
Summary
LinkedIn post on Regeneron’s Praluent pricing and market rollout The passage discusses drug pricing, market expectations, and physician usage surveys for Praluent. It contains no concrete allegations, financial flows, or links to high‑profile political or intelligence actors. The information is largely public and offers no actionable investigative leads. Key insights: Regeneron CEO Leonard Schleifer comments on pricing and access.; Praluent price is 46% higher than analyst forecasts.; Physician survey suggests broader off‑label use than label.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.